Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Group

Summary of Main Points from the Meeting held on Monday 9th July 2018

2. Minutes and Summary Notes from last meeting

The Minutes and Summary notes from the 11th June 2018 Medicines Group meeting were approved and will be circulated.

3. Matters Arising

The Group noted the matters arising from the previous meeting.

4. Business to be transacted by the Medicines Group

4.1 Formulary Applications

Full Applications

- **Patiromer Sachets 8.4g and 16.8g Powder for Oral Suspension (Veltassa®)**

Requested by the Heart Failure Team for patients with heart failure with drug related hyperkalaemia. Veltassa® may be used to enable dose optimisation and continued the use of desirable renin-angiotensin-aldosterone-system inhibitors therapy in patients with treatment related hyperkalaemia. It is not expected that GPs will be asked to undertake the ongoing prescribing once initiated in secondary care on account of the need to undertake close monitoring of patients. There will be a potential cost to the Trust of £51k-£103k per annum.
Decision: Approved for addition to the formulary

Ex-panel

- **Adalimumab 20mg pre-filled syringes**

Adalimumab is used at licenced doses of 20mg in paediatric IBD. Currently 40mg pre-filled syringes which are included on the formulary are issued. During administration, part of the syringe contents are discarded to give the required dose.
Proposal is to add 20mg pre-filled syringes to the formulary in addition, which are more cost-effective for the administration of small doses. This addition to the formulary will also support home administration.
Decision: Approved for addition to the formulary

Removals

- **Premarin and Prempak C preparations**
  - Oestrogens conjugated 0.625mg tablet - Premarin
  - Oestrogens conjugated 1.25mg tablet - Premarin
  - Prempak C 0.625mg tablet
  - Prempak C 1.25mg tablet

Discontinued by the manufacturer
Decision: Approved for removal from the formulary

NICE Approved drug applications

- **Guselkumab 100mg Injection (Tremfya®) in line with NICE TA521 for Moderate to Severe Plaque**

Application form for drug approved by NICE.
Decision: Approved for addition to the formulary

Pharmacoeconomic Board requests

- Nil

4.2 Trust Medicines Policy

- **TMP - Section 34: Administration of medicines by Healthcare Assistants and Assistant Practitioners**

New section to the Trust Medicines Policy.
Provides a governance framework for HCAs/APs to undertake the role of medicines administration at Chelsea and Westminster Hospital NHS Foundation. This procedure outlines the process involved and necessary

training and competencies required to ensure the safe administer of medicines by HCAs and APs in specific clinical scenarios as approved by the Trust Medicines Group.
The first clinical scenario that has been approved by the Nursing & Midwifery Group involving the administration of IM vaccines in the HIV/GUM Directorate was presented.
Decision: Approved

- **TMP - Section 35: Individual Funding Request Policy**

Routine review and update of existing policy
Adapted to form part of a new section of the Trust Medicines Policy.
Decision: Approved

- **TMP - Section 7: Unlicensed Medicinal Products**

Scheduled review and update.
Harmonised across both hospital sites.
Changes in MHRA terminology and legislation incorporated into the policy.
Updated to include Boots outsourced out-patients sites.
The Pharmacoeconomic Board will act as the approving body where there is insufficient evidence available to support the use of an UMP Category B.
Decision: Approved

4.3 Medicines Optimisation

- **Referral proformas for OPAT patients on Evolve**

Proposal regarding the introduction of referral proformas for OPAT patients on Evolve that includes a means of recording medication orders and administration records.
This will mean that prescribing and administration will be undertaken electronically. It will also mean it will be possible to retrieve data regarding OPAT prescribing centrally for the national Outcome Register.

The pre-populated proformas for Pyleonephritis, Community Acquired Pneumonia and Cellulitis cover about 80% of infections treated via the OPAT Service.

The more complex infections (~20% of Ambulatory Care patients) – abscesses/osteomyelitis are not covered by the pre-populated prescribing proformas but they will still have an electronic referral system on Evolve. For some of these patients a generic Hetrogenous electronic proforma will be used. A standard paper drug chart will be used for those patients who require weeks/months of IV antibiotic therapy. A more permanent electronic solution will be established for these patients using the electronic Cerner prescribing system once this is in place.
Decision: Drug proformas approved for use in the Trust as part of the referral pathway

4.4 NICE Technical Appraisals and Guidance
NICE Technical Appraisals

6 Appraisal published in June 2018

TA521 - Guselkumab for treating moderate to severe plaque psoriasis
Formulary status / Action
Add to the formulary - See application form included in Section 4.1

TA522 - Pembrolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
Formulary status / Action
Currently included on the formulary. Numbers likely to treat at CWH site: 1-2 patients per year.

TA523 - Midostaurin for untreated acute myeloid leukaemia
Formulary status / Action
Not applicable to C&W - Specialist Centres only and C&W is not a commissioning Centre

Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Group

TA524 - Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
Formulary status / Action
Currently included on the formulary.

TA525 - Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
Formulary status / Action
Currently included on the formulary.

TA526 - Arsenic trioxide for treating acute promyelocytic leukaemia
Formulary status / Action
Nil action - Not applicable to C&W.

4.5 IVIG requests

CWH Site

- IVIG issues for June 2018 - CW site

There were 8 IVIG issues in June 2018, with 2 new requests

WMUH Site

- IVIG issues for April 2018 - WMUH site

There were 18 IVIG issues in April 2018, with 2 new requests:

- IVIG issues for May 2018 - WMUH site

There were 16 IVIG issues in May 2018, with 2 new requests

- IVIG issues for June 2018 - WMUH site

There were 18 IVIG issues in June 2018, with 6 new requests:
Decision: Approved

4.6 Items for noting

- **Pharmacy Clinical Audit Programme - 2017-2018**

Pharmacy Clinical Audit programme updated as of June 2018
Decision: Noted

- **Audit: The appropriateness of inpatient prescribing of Atovaquone**

Audit report for noting
Decision: Noted

- **CPP Report - June 2018**

CCP Report for June 2018
Decision: Noted

- **MHRA Drug Safety Update - June 2018**

MHRA update for June 2018
Decision: Noted

4.7 Meeting minutes for noting

- **Antimicrobial Steering Group Meeting - May 2018**

Minutes from Antimicrobial Steering Group Meeting - May 2018
Decision: Noted

- **HIV/GUM Directorate - Medicines Sub-Group Meeting - May 2018**

Minutes from HIV/GUM Directorate - Medicines Sub-Group Meeting - May 2018
Decision: Noted

Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Group

- **Medicines Safety Group Meeting - June 2018**

Minutes from Medication Safety Group Meeting - June 2018
Decision: Noted

4.8 Additional papers to go to Trust patient Safety Group

- Nil

5. Any other business

- **Double signing of Mifepristone**

Mifepristone is currently treated as a controlled Drug in the Trust in line with the Trust Medicine Policy based on good practice but this is not a legal requirement. It was agreed following a request received from Gynaecology Out-patient Clinic that Mifeprisone will no longer be subject to double signing as is the case for all controlled drugs.
Decision: Trust Medicines Policy will be updated to reflect that Mifepristone will no longer be subject to double signing.

6. Date of next meeting

Date: Monday 10th September 2018
Time: 8am-9am
Location: Board Room (CWH Site) and Meeting Room A (WMUH Site via video conferencing)
Closing date: 17th August 2018